Search
For Your SweetHeart | Infographic
Biotherapeutics Modalities Infographic
Meet our Team
Meet Our Team
World Water Day 2019 | Boehringer Ingelheim US
Click here to find out more on the steps Boehringer Ingelheim are taking on World Water Day 2019 to support animal shelters in Mexico City.
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
What to Expect from Your Vaccine | Boehringer Ingelheim US
Read more on how horse owners are encouraged to schedule a wellness exam with their veterinarians, including annual equine vaccinations.
IT at BI
Discover firsthand what IT does at BI #IdoIT
Dr. Anna Dieckmann and Dr. Lorenz Maier
Here is the story of Dr. Anna Dieckmann and Dr. Lorenz Maier's successful partnership. For more talent insights, visit our Careers Page.
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US
Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
Work life wellness
We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
Why role models matter for black veterinarians: One doctor's story
Why role models matter for black veterinarians: One doctor's story
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
PolyMast Mastitis Tube Introduced | Boehringer Ingelheim US
Find out more about the new name in the mastitis tube market, cutting down today's regular 5-day treatment to just 3: PolyMast from Boehringer Ingelheim.
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
African Swine Fever: Important Facts | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.
From Finance to Pharma
From Finance to Pharma
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations